Humana Inc. (NYSE:HUM) Shares Acquired by Gateway Investment Advisers LLC

Gateway Investment Advisers LLC increased its holdings in shares of Humana Inc. (NYSE:HUM) by 53.4% in the first quarter, Holdings Channel reports. The firm owned 3,629 shares of the insurance provider’s stock after acquiring an additional 1,263 shares during the period. Gateway Investment Advisers LLC’s holdings in Humana were worth $960,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Transcend Capital Advisors LLC boosted its position in Humana by 399.7% during the 4th quarter. Transcend Capital Advisors LLC now owns 3,643 shares of the insurance provider’s stock worth $924,000 after purchasing an additional 2,914 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Humana by 7.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 964,926 shares of the insurance provider’s stock worth $244,811,000 after purchasing an additional 65,735 shares during the period. denkapparat Operations GmbH purchased a new stake in Humana during the 4th quarter worth $323,000. South Dakota Investment Council boosted its position in Humana by 39.9% during the 4th quarter. South Dakota Investment Council now owns 153,317 shares of the insurance provider’s stock worth $38,898,000 after purchasing an additional 43,719 shares during the period. Finally, Allstate Corp purchased a new stake in Humana during the 4th quarter worth $905,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Performance

Shares of HUM stock opened at $230.36 on Monday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a one year low of $212.45 and a one year high of $406.46. The company’s 50-day simple moving average is $253.49 and its 200-day simple moving average is $264.69. The stock has a market capitalization of $27.80 billion, a price-to-earnings ratio of 23.15, a PEG ratio of 2.05 and a beta of 0.43.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping the consensus estimate of $10.07 by $1.51. Humana had a net margin of 1.02% and a return on equity of 11.70%. The business had revenue of $32.11 billion for the quarter, compared to analysts’ expectations of $32 billion. During the same quarter last year, the company posted $7.23 earnings per share. The company’s quarterly revenue was up 8.4% compared to the same quarter last year. Equities analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a yield of 1.54%. Humana’s dividend payout ratio is currently 25.04%.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Guggenheim assumed coverage on shares of Humana in a research report on Wednesday, April 9th. They set a “buy” rating and a $326.00 price target for the company. Robert W. Baird upped their price objective on shares of Humana from $270.00 to $300.00 and gave the company a “neutral” rating in a research report on Tuesday, April 15th. Barclays decreased their price objective on shares of Humana from $322.00 to $273.00 and set an “equal weight” rating for the company in a research report on Monday, June 2nd. JPMorgan Chase & Co. decreased their price objective on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research report on Tuesday, February 18th. Finally, Raymond James raised shares of Humana from a “market perform” rating to an “outperform” rating and set a $315.00 price objective for the company in a research report on Thursday, May 1st. Sixteen investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Humana has a consensus rating of “Hold” and a consensus price target of $284.48.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.